New Strains of <i>Akkermansia muciniphila</i> and <i>Faecalibacterium prausnitzii</i> are Effective for Improving the Muscle Strength of Mice with Immobilization-Induced Muscular Atrophy
Hye Rim Byeon, Seo-Yul Jang, Yoonmi Lee, Dohak Kim, Moon-Gi Hong, Dokyung Lee, Joo‐Hyun Shin, Jae‐Gu Seo
Abstract
Muscular atrophy is a muscle disease in which muscle mass and strength decrease due to aging, injury, metabolic disorders, or chronic conditions. Proteins in muscle tissue are degraded by the ubiquitin-proteasome pathway, and atrophy accelerates this pathway. Akkermansia muciniphila and Faecalibacterium prausnitzii strains are effective agents against metabolic and inflammatory diseases in next-generation probiotic research. In this study, we evaluated the efficacy of A. muciniphila strain EB-AMDK19 and F. prausnitzii strain EB-FPDK11 in a mouse model of muscular atrophy, since atrophy inhibits energy metabolism and immune activation. After oral administration of each strain for 4 weeks, the hind legs of the mice were fixed with a plaster cast to immobilize them for a week. As a result, the administration of EB-AMDK19 and EB-FPDK11 strains improved grip strength but did not increase muscle mass. At the molecular level, A. muciniphila and F. prausnitzii treatments decreased the expression levels of ubiquitin-proteasome genes, atrogin-1 , MuRF , and cathepsin L . They increased the expression level of the mitochondrial biogenesis regulatory gene, PGC-1α . The effect of the strains was confirmed by a decrease in myostatin. Furthermore, A. muciniphila and F. prausnitzii modulated the immune function by enhancing ZO-1 and inhibiting IL-6 . In particular, EB-AMDK19 promoted the expression of IL-10 , an anti-inflammatory cytokine. These results suggest that A. muciniphila and F. prausnitzii may have beneficial effects on muscular atrophy, verified by newly isolated EB-AMDK19 and EB-FPDK11 as potential next-generation probiotics.